<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 11pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: normal 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Current Report Pursuant to Section&nbsp;13
or 15(d) of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Date of Report (Date of earliest event reported):
January 19, 2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>GENEREX BIOTECHNOLOGY CORPORATION</B></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Exact name of registrant as specified in
its charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 34%; vertical-align: top; line-height: 115%; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 1%; vertical-align: bottom; line-height: 115%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; vertical-align: top; line-height: 115%; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>000-29169</B></FONT></TD>
    <TD STYLE="width: 1%; vertical-align: bottom; line-height: 115%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; vertical-align: bottom; line-height: 115%; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>98-0178636</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>(State
        or other jurisdiction of</B></FONT></P>
        <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>incorporation)</B></FONT></P></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 115%; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Commission
    File Number)</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 115%; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>(I.R.S
    Employer Identification No.)</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; line-height: 115%; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 115%; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 115%; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top; line-height: 115%; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>33
    Harbour Square, Suite 202, Toronto, Ontario Canada</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 115%; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>M5J
    2G2</B></FONT></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top; line-height: 115%; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Address
    of principal executive offices)</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 115%; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Zip
    Code)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Registrant&rsquo;s telephone number, including
area code: (416) 364-2551</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>N/A</B></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Former name or former address, if changed
since last report.)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; line-height: 115%; font-family: Calibri, Halvetica, Sans-Serif"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></FONT></TD>
    <TD STYLE="width: 96%; line-height: 115%"><FONT STYLE="font-size: 10pt">Written communications pursuant to Rule 425 under
    the Securities Act (17 CFR 230.425)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; line-height: 115%; font-family: Calibri, Halvetica, Sans-Serif"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></FONT></TD>
    <TD STYLE="width: 96%; line-height: 115%"><FONT STYLE="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under
    the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; line-height: 115%; font-family: Calibri, Halvetica, Sans-Serif"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD>
    <TD STYLE="width: 96%; line-height: 115%"><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b)
    under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; line-height: 115%; font-family: Calibri, Halvetica, Sans-Serif"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD>
    <TD STYLE="width: 96%; line-height: 115%"><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c)
    under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif"><B>Item
1.01.&#9;Entry into a Material Definitive Agreement</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item
2.03.&#9;Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant</B></FONT><B>
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On January 19, 2012, two wholly owned subsidiaries
of Generex Biotechnology Corporation (&ldquo;Generex&rdquo;) received mortgage loans in the aggregate amount of CDN $2,500,000
[US $2,475,000 ] from a private lender. The loans were secured by real estate owned by the subsidiaries in Ontario. Generex is
a guarantor of the loans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The properties are subject to a prior mortgage
of approximately CDN $1.1 million [US $1.1 million]. An amount equal to the balance of the prior mortgage was placed into escrow
pending the subsequent funding described below. After this amount was placed in escrow and deduction of expenses, the subsidiaries
received net proceeds of approximately CDN $1.1 million [US $1.1 million].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The subsidiaries have received a commitment
from the lender for an additional CDN $1.1 million [US $1.1 million] loan. Generex expects to close on the additional loan in the
near future, although the additional loan is still subject to fulfillment of certain conditions. If the subsidiaries receive the
additional loan, the prior mortgage will be repaid with the proceeds of the new loan, and the subsidiaries are expected to receive
proceeds of approximately CDN $1.1 million [US $1.1 million] less expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Interest on the loans is payable monthly at
the rate of 10% per annum. The principal amount is due and payable one year after the closing of the loans.</P>

<P STYLE="font: 11pt Calibri, Halvetica, Sans-Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Statements in this report may contain certain
forward-looking statements. All statements included concerning activities, events or developments that Generex expects, believes
or anticipates will or may occur in the future are forward-looking statements. Actual results could differ materially from the
results discussed in the forward-looking statements. Forward-looking statements are based on current expectations and projections
about future events and involve known and unknown risks, uncertainties and other factors that may cause actual results and performance
to be materially different from any future results or performance expressed or implied by forward-looking statements. Known risks
and uncertainties also include those identified from time to time in the reports filed by Generex with the Securities and Exchange
Commission (&ldquo;SEC&rdquo;), which should be considered together with any forward-looking statement. No forward-looking statement
is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes
no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation
Reform Act. Additional information on these and other risks, uncertainties and factors is included in Generex&rsquo;s Annual Report
on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other documents filed with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; line-height: 115%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 49%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>GENEREX BIOTECHNOLOGY</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>CORPORATION</B>.</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="line-height: 115%; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%; font-size: 10pt">Date: January 24, 2011</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%; font-size: 10pt">/s/ Mark A. Fletcher</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="line-height: 115%; font-size: 10pt">Mark A. Fletcher</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="line-height: 115%; font-size: 10pt">President and Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v300249_8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 16848}]
{"company-data": {"conformed-name": "GENEREX BIOTECHNOLOGY CORP", "cik": "0001059784", "assigned-sic": "2834", "irs-number": "820490211", "state-of-incorporation": "DE", "fiscal-year-end": "0731"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-25169", "film-number": "12542061"}, "business-address": {"street1": "33 HARBOUR SQ", "street2": "STE 202", "city": "TORONTO ONTARIO CANADA", "state": "A1", "zip": "M5J 2G2", "phone": "4163642551"}, "mail-address": {"street1": "33 HARBOUR SQ", "street2": "STE 202", "city": "TORONTO ONTARIO CA", "state": "A1", "zip": "M5J 2G2"}}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13
or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 19, 2012
GENEREX BIOTECHNOLOGY CORPORATION
(Exact name of registrant as specified in
its charter)
Delaware
000-29169
98-0178636
(State
        or other jurisdiction of
incorporation)
(Commission
    File Number)
(I.R.S
    Employer Identification No.)
33
    Harbour Square, Suite 202, Toronto, Ontario Canada
M5J
    2G2
(Address
    of principal executive offices)
(Zip
    Code)
Registrant's telephone number, including
area code: (416) 364-2551
N/A
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
£
Written communications pursuant to Rule 425 under
    the Securities Act (17 CFR 230.425)
£
Soliciting material pursuant to Rule 14a-12 under
    the Exchange Act (17 CFR 240.14a-12)
£
Pre-commencement communications pursuant to Rule 14d-2(b)
    under the Exchange Act (17 CFR 240.14d-2(b))
£
Pre-commencement communications pursuant to Rule 13e-4(c)
    under the Exchange Act (17 CFR 240.13e-4(c))
Item
1.01.	Entry into a Material Definitive Agreement
Item
2.03.	Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
On January 19, 2012, two wholly owned subsidiaries
of Generex Biotechnology Corporation ("Generex") received mortgage loans in the aggregate amount of CDN $2,500,000
[US $2,475,000 ] from a private lender. The loans were secured by real estate owned by the subsidiaries in Ontario. Generex is
a guarantor of the loans.
The properties are subject to a prior mortgage
of approximately CDN $1.1 million [US $1.1 million]. An amount equal to the balance of the prior mortgage was placed into escrow
pending the subsequent funding described below. After this amount was placed in escrow and deduction of expenses, the subsidiaries
received net proceeds of approximately CDN $1.1 million [US $1.1 million].
The subsidiaries have received a commitment
from the lender for an additional CDN $1.1 million [US $1.1 million] loan. Generex expects to close on the additional loan in the
near future, although the additional loan is still subject to fulfillment of certain conditions. If the subsidiaries receive the
additional loan, the prior mortgage will be repaid with the proceeds of the new loan, and the subsidiaries are expected to receive
proceeds of approximately CDN $1.1 million [US $1.1 million] less expenses.
Interest on the loans is payable monthly at
the rate of 10% per annum. The principal amount is due and payable one year after the closing of the loans.
Forward-Looking Statements
Statements in this report may contain certain
forward-looking statements. All statements included concerning activities, events or developments that Generex expects, believes
or anticipates will or may occur in the future are forward-looking statements. Actual results could differ materially from the
results discussed in the forward-looking statements. Forward-looking statements are based on current expectations and projections
about future events and involve known and unknown risks, uncertainties and other factors that may cause actual results and performance
to be materially different from any future results or performance expressed or implied by forward-looking statements. Known risks
and uncertainties also include those identified from time to time in the reports filed by Generex with the Securities and Exchange
Commission ("SEC"), which should be considered together with any forward-looking statement. No forward-looking statement
is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes
no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation
Reform Act. Additional information on these and other risks, uncertainties and factors is included in Generex's Annual Report
on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other documents filed with the SEC.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
GENEREX BIOTECHNOLOGY
CORPORATION
.
Date: January 24, 2011
/s/ Mark A. Fletcher
Mark A. Fletcher
President and Chief Executive Officer